Industry News
Biotechnology Industry News
A pair of phase 3 psoriasis…
A pair of phase 3 psoriasis studies of Alumis’ TYK2 inhibitor have hit their primary endpoints, setting the biotech up to file for approval of a potential challenger to Bristol Myers Squibb’s Sotyktu. With the
Instil Bio’s hopes for its…
Instil Bio’s hopes for its refreshed clinical pipeline appear to have ended in failure, with the U.S. biotech handing the rights to two drugs back to their original owner.
U.K. biotech Ikarovec has teamed…
U.K. biotech Ikarovec has teamed up with VectorBuilder to work on an eye disease gene therapy that could be administered in a doctor’s office.
Less than two weeks after…
Less than two weeks after rejecting Sanofi’s investigational multiple sclerosis drug, the FDA has publicly shared the complete response letter, citing both efficacy and safety concerns, including a case of serious liver injury that led
Pfizer is penning a cancer…
Pfizer is penning a cancer discovery pact with Cartography Biosciences that could max out at $865 million biobucks.
Gilead Sciences has found a shiny…
Gilead Sciences has found a shiny new package for one of its cancer assets, inking an up to $300 million research pact for access to OncoNano Medicine’s tumor-targeting lipid particles.
MetaVia has shared an update on…
MetaVia has shared an update on its attempt to crash the obesity party, reporting average weight loss of 9.1% in people who received its dual agonist of GLP-1 and glucagon in a phase 1 trial.
With the result falling short of…
With the result falling short of the bar Amgen set in another study, investors sent Zenas’ share price down 48% to $18 in premarket trading.
Aktis Oncology is aiming to bring…
Aktis Oncology is aiming to bring in $182 million—or more—from what looks set to be the first biotech IPO of 2026.
Sanofi has returned to U.S….
Sanofi has returned to U.S. artificial intelligence research biotech Earendil Labs for another significant autoimmune and immunology development pact.
The Singapore Eye Research…
The Singapore Eye Research Institute has pulled out of a collaboration with TME Pharma less than seven months after cementing their work on an eye disease program.
In 2025, biopharma layoffs showed…
In 2025, biopharma layoffs showed no signs of slowing, instead rising 16% year over year.
After five years, Nido Biosciences…
After five years, Nido Biosciences has reached the end of the road, closing its doors after its lead neurological disease candidate disappointed in a midstage study.
AbbVie and Gilead each used the…
AbbVie and Gilead each used the holiday season to reward their pipelines with a new clinical-stage cancer drug.
Johnson & Johnson and Genmab…
Johnson & Johnson and Genmab both used the festive period to junk therapies that haven’t lived up to their promise in the clinic.
Ultragenyx Pharmaceutical has…
Ultragenyx Pharmaceutical has reported the failure of a pair of late-phase brittle bone disease trials, prompting the biotech to prepare to significantly reduce its spending.
As the biopharma wound down for…
As the biopharma wound down for the holidays, the company reported the failure of a midphase study of BHV-7000 for the treatment of major depressive disorder.
The festive period brought some…
The festive period brought some unwanted post for both Sanofi and Corcept Therapeutics in the form of FDA rejections for the companies’ respective drug applications.
Zai Lab President and COO Josh…
Zai Lab President and COO Josh Smiley explains how speed, scale and rigor are reshaping global drug development
Mirum Pharmaceuticals is applying…
Mirum Pharmaceuticals is applying a disciplined rare disease strategy to build a high-impact portfolio. Tune in to The Top Line as Ajay Narasimha discusses pipeline momentum, strategic M&A, and how the recent Bluejay acquisition fits